Live vaccinia-rabies virus recombinants, but not an inactivated rabies virus cell culture vaccine, protect B-lymphocyte-deficient A/WySnJ mice against rabies: Considerations of recombinant defective poxviruses for rabies immunization of immunocompromised individuals

Vaccine

Volumn 22, Issue 25-26, 2004, Pages 3329-3333

  Lodmell, Donald L ^a   Esposito, Joseph J ^b   Ewalt, Larry C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

A WySnJ mice; Cell culture vaccine; Immunosuppression; Rabies virus; Vaccinia virus recombinant

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; LIVE VACCINE; NEUTRALIZING ANTIBODY; RABIES VACCINE; VACCINIA VACCINE; VIRUS NUCLEOPROTEIN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL COUNT; CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNIZATION; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; RABIES; RABIES VIRUS; T LYMPHOCYTE;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CELLS, CULTURED; FEMALE; IMMUNOCOMPROMISED HOST; MICE; MICE, INBRED STRAINS; MUTATION; NEUTRALIZATION TESTS; RABIES; RABIES VACCINES; RABIES VIRUS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 4043174189     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.02.039     Document Type: Article

References (43)

1. Fishbein D.B., Robinson L.E. Rabies N. Engl. J. Med. 329:1993;1632-1638
2. Meslin F, Fishbien DB, Matter HC. Rationale and prospects for rabies elimination in developing countries. In: Rupprecht CE, Dietzschold B, Koprowski H, editors. Lyssaviruses. New York: Springer Verlag, 1994. p. 1-26.
3. Dressen D.W. A global review of rabies vaccines for human use. Vaccine. 15(Suppl.):1997;S2-S6
4. Hoenig L.J. Triumph and controversy. Pasteur's preventive treatment of rabies as reported in JAMA. Arch. Neurol. 43:1986;397-399
5. Wiktor T.J., Sokol F., Kuwert E., Koprowski H. Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin. Proc. Soc. Exp. Biol. Med. 131:1969;799-805
6. Barth R., Gruschkau H., Bijok U., Hifenhaus J., Hinz J., Milcke L., et al. A new inactivated tissue culture rabies vaccine for use in man: Evaluation of PCEC vaccine by laboratory tests. J. Biol. Stand. 12:1984;29-46
7. Barth R, Franke V. Renal rhesus monkey lung diploid cell vaccine for humans. In: Meslin F-X, Kaplan MM, Koprowski H, editors. Laboratory techniques in rabies. 4th ed. Geneva: World Health Organization, 1996. p. 297-300.
8. Tantawichien T., Jaijaroensup W., Khawplod P., Sitprija V. Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. Clin. Infect. Dis. 33:2001;E122-E124
9. Pancharoen C., Thisyakorn U., Tantawichien T., Jaijaroensup W., Khawplod P., Wilde H. Failure of pre- and postexposure rabies vaccinations in a child infected with HIV. Scand. J. Infect. Dis. 33:2001;390-391
10. Thisyakorn U., Pancharoen C., Ruxrungtham K., Ubolyam S., Khawplod P., Tantawichien T., et al. Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1. Clin. Infect. Dis. 30:2000;218
11. Jaijaroensup W., Tantawichien T., Khawplod P., Tepsumethanon S., Wilde H. Postexposure rabies vaccination in patients infected with human immunodeficiency virus. Clin. Infect. Dis. 28:1999;913-914
12. Taylor D.N., Wasi C., Bernard K. Chloroquine prophylaxis associated with a poor antibody response to human diploid cell rabies vaccine. Lancet. 1:1984;1405
13. Pappaioanou M., Fishbein D.B., Dreesen D.W., Schwartz I.K., Campbell G.H., Sumner J.W., et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N. Engl. J. Med. 314:1986;280-284
14. Hay E., Derazon H., Bukish N., Scharf S., Rishpon S. Postexposure rabies prophylaxis in a patient with lymphoma. JAMA. 285:2001;166-167
15. Bernard K.W., Fishbein D.B., Miller K.D., Parker R.A., Waterman S., Sumner J.W., et al. Pre-exposure rabies immunization with human diploid cell vaccine: decreased antibody responses in persons immunized in developing countries. Am. J. Trop. Med. Hyg. 34:1985;633-647
16. Bunschoten H., Gore M., Claassen I.J.T.M., Uytdehaag F.G.C.M., Dietzschold B., Wunner W.H., et al. Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. J. Gen. Virol. 70:1989;291-298
17. Charlton K.M., Artois M., Prevec L., Campbell J.B., Casey G.A., Wandeler A.I., et al. Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Arch. Virol. 123:1992;169-179
18. Lodmell D.L. Genetic control of resistance to street rabies virus in mice. J. Exp. Med. 157:1983;451-460
19. Esposito J., Brechling K., Baer G., Moss B. Vaccinia virus recombinants expressing rabiesvirus glycoprotein protect against rabies. Virus Genes. 1:1987;7-21
20. Lafon M., Wiktor T.J., Macfarlan R.I. Antigenic sites on the CVS rabies virus glycoprotein: analysis with monoclonal antibodies. J. Gen. Virol. 64:1983;843-851
21. Lodmell D.L., Ewalt L.C. Pathogenesis of street rabies virus infections in resistant and susceptible strains of mice. J. Virol. 55:1985;788-795
22. + T cells in murine resistance to street rabies virus. J. Virol. 65:1991;3429-3434
23. Lodmell D.L., Ray N.B., Parnell M.J., Ewalt L.C., Hanlon C.A., Shaddock J.H., et al. DNA immunization protects nonhuman primates against rabies virus. Nat. Med. 4:1998;949-952
24. Fekadu M., Sumner J.W., Shaddock J.H., Sanderlin D.W., Baer G.M. Sickness and recovery of dogs challenged with a street rabies virus after vaccination with a vaccinia virus recombinant expressing rabies virus N protein. J. Virol. 66:1992;2601-2604
25. Lodmell D.L., Sumner J.W., Esposito J.J., Bellini W.J., Ewalt L.C. Raccoon poxvirus recombinants expressing the rabies virus nucleoprotein protect mice against lethal rabies virus infection. J. Virol. 65:1991;3400-3405
26. Sumner J.W., Fekadu M., Shaddock J.H., Esposito J.J., Bellini W.J. Protection of mice with vaccinia virus recombinants that express the rabies nucleoprotein. Virology. 183:1991;703-710
27. Fu Z.F., Dietzschold B., Schumacher C.L., Wunner W.H., Ertl H.C.J., Koprowski H. Rabies virus nucleoprotein expressed in and purified from insect cells is efficacious as a vaccine. Proc. Natl. Acad. Sci. U.S.A. 88:1991;2001-2005
28. Dietzschold B., Wang H., Rupprecht C.E., Celis E., Tollis M., Ertl H., et al. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc. Natl. Acad. Sci. U.S.A. 84:1987;9165-9169
29. Lodmell D.L., Esposito J.J., Ewalt L.C. Rabies virus anti-nucleoprotein antibody protects against rabies virus challenge in vivo and inhibits rabies virus replication in vitro. J. Virol. 67:1993;6080-6086
30. Drings A., Jallet C., Chambert B., Tordo N., Perrin P. Is there an advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine? Vaccine. 17:1999;1549-1557
31. Miller D.J., Hayes C.E. Phenotypic and genetic characterization of a unique B lymphocyte deficiency in strain A/WySnJ mice. Eur. J. Immunol. 21:1991;1123-1130
32. Miller D.J., Hanson K.D., Carman J.A., Hayes C.E. A single autosomal gene defect severely limits IgG but not IgM responses in B lymphocyte-deficient A/WySnJ mice. Eur. J. Immunol. 22:1992;373-379
33. Lodmell D.L., Smith J.S., Esposito J.J., Ewalt L.C. Cross-protection of mice against a global spectrum of rabies virus variants. J. Virol. 69:1995;4957-4962
34. Zhao W.G., Azaibi T., Zhu J.H., Wang J.L., Cai B., Esposito J.J. Co-expression of rabies virus glycoprotein and nucleoprotein in vaccinia virus Tian Tan strain. Viral. Senica. 10:1995;15-21
35. Zhu J.H., Wang J., Cai B., Zhao W., Zhu Y., Chao R., et al. Immunogenicity and relative attenuation of different vaccinia-rabies virus recombinants. Arch. Virol. 141:1996;1055-1065
36. Lafon M., Lafage M., Martinez-Arends A., Ramirez R., Vuillier F., Charron D., et al. Evidence for a viral superantigen in humans (see comments). Nature. 358:1992;507-510
37. Lafon M., Scott-Algara D., Marche P.N., Cazenave P.A., Jouvin-Marche E. Neonatal deletion and selective expansion of mouse T cells by exposure to rabies virus nucleocapsid superantigen. J. Exp. Med. 180:1994;1207-1215
38. Taylor J., Trimarchi C., Weinberg R., Languet B., Guillemin F., Desmettre P., et al. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine. 9:1991;190-193
39. Cadoz M., Strady A., Meignier B., Taylor J., Tartaglia J., Paoletti E., et al. Immunization with canarypox virus expressing rabies glycoprotein. Lancet. 339:1992;1429-1432
40. Taylor J., Weinberg R., Languet B., Desmettre P., Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine. 6:1988;497-503
41. Taylor J., Meignier B., Tartaglia J., Languet B., VanderHoeven J., Franchini G., et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 13:1995;539-549
42. Fries L.F., Tartaglia J., Taylor J., Kauffman E.K., Meignier B., Paoletti E., et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine. 14:1996;428-434
43. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc. Natl. Acad. Sci. U.S.A. 93:1996;11349-11353